Results 21 to 30 of about 24,396 (218)
Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
Journal of Immunology Research, 2023 Background. CD47 has high levels of expression in malignant cancer cells, which binds to SIRP-α to release the “don’t eat me” signal and prevents mononuclear macrophages from phagocytosing the cells.
Qianqian Wang +8 more
doaj +1 more source
Regulation of CD47 expression on CD14+ monocytes by interferon-α in PBC patients
Frontiers in Immunology, 2023 BackgroundPrimary biliary cholangitis (PBC) is a chronic intrahepatic cholestatic autoimmune liver disease characterized by inflammatory injury of small and medium-sized bile ducts in the liver.
Xi Su +8 more
doaj +1 more source
The CD47-SIRPα Immune Checkpoint
Immunity, 2020 The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted through inhibitory and activating receptors. The Cluster of Differentiation 47 (CD47) protein, expressed on both healthy and cancer cells, plays a pivotal role in this balance by delivering a "don't eat me signal" upon binding to the Signal-regulatory ...
Meike E.W. Logtenberg +2 more
openaire +3 more sources
Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice
OncoImmunology, 2022 CD47 has established roles in the immune system for regulating macrophage phagocytosis and lymphocyte activation, with growing evidence of its cell-intrinsic regulatory roles in natural killer and CD8+ T cells.
Pulak R. Nath +6 more
doaj +1 more source
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas
OncoImmunology, 2020 Early trials for immune checkpoint inhibitors in sarcomas have delivered mixed results, and efforts to improve outcomes now look to combinatorial strategies with novel immunotherapeutics, including some that target macrophages.
Amanda R. Dancsok +8 more
doaj +1 more source
Thoracic Cancer, 2022 Background Recent studies indicated that T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) and cluster of differentiation 47 (CD47) have emerged as new potential immunotherapy targets.
Yue Peng +13 more
doaj +1 more source
Frontiers in Immunology, 2018 CD47 is a ubiquitous cell surface receptor that directly regulates T cell immunity by interacting with its inhibitory ligand thrombospondin-1 and limits clearance of cells by phagocytes that express its counter-receptor signal-regulatory protein-α ...
Pulak Ranjan Nath +8 more
doaj +1 more source
Clinical and Translational MedicineAbstractCluster of differentiation 47 (CD47) occupies the outer membrane of human cells, where it binds to soluble and cell surface receptors on the same and other cells, sculpting their topography and resulting in a pleiotropic receptor‐multiligand interaction network.
Jeffrey S. Isenberg, Enrique Montero
openaire +3 more sources
Animal Cells and Systems, 2020 CD47 is a tumor-associated antigen best known for its ability to bind counter-receptors on the surface of professional phagocytes as an immune-evasion strategy.
Pascal Leclair, Chinten James Lim
doaj +1 more source
On the mechanism of CD47 targeting in cancer [PDF]
Proceedings of the National Academy of Sciences, 2012 The report by Willingham et al. (1) is the most recent in a series of publications from the same group, in which the interaction between the broadly expressed surface molecule CD47 and the myeloid inhibitory receptor SIRPα was implicated as a potential therapeutic target in a variety of malignancies. The authors used xenotransplantation models in which
Zhao, Xi Wen +3 more
openaire +5 more sources